VolitionRx Ltd. (NYSE American: VNRX), a multinational epigenetics company, released a consolidated update detailing recent clinical and commercial advancements across its key platforms. The announcement underscores the company's progress in cancer detection, sepsis diagnostics, and veterinary applications, highlighting significant market opportunities and potential milestone payments.
One of the most notable developments is the submission of a manuscript for peer review that introduces a new method called Capture-Seq, along with new biomarkers for cancer detection. Volition estimates this represents an annualized total addressable market opportunity of approximately $23 billion. The method could significantly enhance the company's diagnostic capabilities and expand its commercial reach.
In the cancer diagnostics segment, Volition reported that commercialization of its Nu.Q Cancer assay is advancing in lung cancer. The company noted that its reimbursement submission in France is on track, with routine clinical use expected by Q4 2026. This milestone is critical for establishing a foothold in the European market and generating recurring revenue from the assay.
Volition also confirmed the inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France, which focuses on the early detection of sepsis. Sepsis is a life-threatening condition that requires rapid diagnosis, and the Nu.Q NETs assay could provide a valuable tool for clinicians. Additionally, the company highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, a chronic inflammatory skin condition, noting that the assay is CE-marked and available across Europe.
In the veterinary diagnostics field, Volition reported breakthrough results demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay. The company stated that publication of the feline study is expected to unlock a $5 million contractual milestone payment. This achievement underscores the potential of Volition's technology to address unmet needs in animal health and generate significant non-dilutive funding.
Volition confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and stated that it anticipates announcing additional licensing agreements during 2026. These partnerships could accelerate the commercialization of Volition's assays and expand their global reach. The company's progress across multiple pillars—cancer, sepsis, and veterinary diagnostics—positions it for potential growth and underscores the versatility of its Nu.Q technology platform.
The full press release is available at https://ibn.fm/rgAob. For more information about Volition, visit the company's website at www.Volition.com.
